Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical

Nuclear Medicine and Biology

Volumn 39, Issue 8, 2012, Pages 1142-1151

  Cornelissen, Bart ^a   Darbar, Sonali ^a   Kersemans, Veerle ^a   Allen, Danny ^a   Falzone, Nadia ^a   Barbeau, Jody ^a   Smart, Sean ^a   Vallis, Katherine A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

H2AX; Auger electrons; DNA damage; Ionizing radiation; Radioimmunoconjugate

Indexed keywords

BLEOMYCIN; DNA; DOUBLE STRANDED DNA; GAMMA HISTONE H2AX; GAMMA HISTONE H2AX ANTIBODY TRANSACTIVATOR PROTEIN PENTETATE INDIUM IN 111; HISTONE H2AX; IMMUNOGLOBULIN G TRANSACTIVATOR PROTEIN PENTETATE INDIUM IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL COUNT; CELL SURVIVAL; CLONOGENIC ASSAY; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; IONIZING RADIATION; MOUSE; NONHUMAN; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; BLEOMYCIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HISTONES; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; MICE; MOLECULAR TARGETED THERAPY; PENTETIC ACID; PEPTIDE FRAGMENTS; RADIOMETRY; RADIOPHARMACEUTICALS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84867851565     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.06.001     Document Type: Article

References (36)

1. Begg A.C., Stewart F.A., Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011, 11:239-253.
2. Camphausen K., Tofilon P.J. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 2007, 25:4051-4056.
3. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007, 25:4066-4074.
4. Shewach D.S., Lawrence T.S. Antimetabolite radiosensitizers. J Clin Oncol 2007, 25:4043-4050.
5. Helleday T., Petermann E., Lundin C., Hodgson B., Sharma R.A. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008, 8:193-204.
6. Kassis A.I., Adelstein S.J. Radiobiologic principles in radionuclide therapy. J Nucl Med 2005, 46(Suppl. 1):4S-12S.
7. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998, 273:5858-5868.
8. Nakamura A.J., Rao V.A., Pommier Y., Bonner W.M. The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks. Cell Cycle 2010, 9:389-397.
9. Nakamura A., Sedelnikova O.A., Redon C., Pilch D.R., Sinogeeva N.I., Shroff R., et al. Techniques for gamma-H2AX detection. Methods Enzymol 2006, 409:236-250.
10. Sedelnikova O.A., Bonner W.M. GammaH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle 2006, 5:2909-2913.
11. Kao J., Milano M.T., Javaheri A., Garofalo M.C., Chmura S.J., Weichselbaum R.R., et al. gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets 2006, 6:197-205.
12. Cornelissen B., Kersemans V., Darbar S., Thompson J., Shah K., Sleeth K., et al. Imaging DNA damage in vivo using γH2AX-targeted immunoconjugates. Cancer Res 2011, 71:4539-4549.
13. Costantini D.L., Hu M., Reilly R.M. Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother Radiopharm 2008, 23:3-24.
14. Cornelissen B., Vallis K.A. Targeting the nucleus: an overview of Auger-electron radionuclide therapy. Curr Drug Discov Technol 2010, 7:263-279.
15. Kassis A.I. The amazing world of auger electrons. Int J Radiat Biol 2004, 80:789-803.
16. du Manoir J.M., Francia G., Man S., Mossoba M., Medin J.A., Viloria-Petit A., et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006, 12:904-916.
17. Ripley B.D. Modelling spatial patterns. J R Stat Soc Series B Stat Methodol 1977, 39:172-212.
18. Ripley B.D. Modelling spatial patterns. J R Stat Soc Series B Stat Methodol 1977, 39:21.
19. Collins A.R., Duthie S.J., Dobson V.L. Direct enzymic detection of endogenous oxidative base damage in human lymphocyte DNA. Carcinogenesis 1993, 14:1733-1735.
20. Vojnovic B, Barber PR, Johnston P, Gregory HC, Marples B, Joiner, MC, et al. A high sensitivity, high throughput, automated single-cell gel electrophoresis ('Comet') DNA damage assay Available online at: http://users.ox.ac.uk/~atdgroup/technicalnotes/Comet%20analysis.pdf.
21. Salvat F., Fernandez-Varea J.M., Sempau J. PENELOPE-2008: A Code System for Monte Carlo Simulation of Electron and Photon Transport 2008, 336. PENELOPE-2008, Barcelona, Spain.
22. Eckerman K.F., Endo A. MIRD: radionuclide data and decay schemes 2008, Society of Nuclear Medicine, Reston, VA.
23. Howell R.W. Auger processes in the 21st century. Int J Radiat Biol 2008, 84:959-975.
24. Falzone N., Cornelissen B., Vallis K. Auger emitting radiopharmaceuticals for cancer therapy. Radiation damage in biomolecular systems 2012, 246-252. Springer, Dordrecht, Netherlands. G. García Gómez-Tejedor, M.C. Fuss (Eds.).
25. 111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection. Nucl Med Biol 2008, 35:101-110.
26. 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences. J Nucl Med 2008, 49:1546-1554.
27. 111In in human myeloid leukemia cells. J Nucl Med 2006, 47:827-836.
28. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
29. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
30. Oka K, Tanaka T, Enoki T, Yoshimura K, Ohshima M, Kubo, M, et al. DNA damage signaling is activated during cancer progression in human colorectal carcinoma. Cancer Biol Ther 9.
31. Wasco M.J., Pu R.T., Yu L., Su L., Ma L. Expression of gamma-H2AX in melanocytic lesions. Hum Pathol 2008, 39:1614-1620.
32. Rayne F., Debaisieux S., Yezid H., Lin Y.L., Mettling C., Konate K. Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells. EMBO J 2010, 29:1348-1362.
33. Datta K., Jaruga P., Dizdaroglu M., Neumann R.D., Winters T.A. Molecular analysis of base damage clustering associated with a site-specific radiation-induced DNA double-strand break. Radiat Res 2006, 166:767-781.
34. Goddu S.M., Howell R.W., Rao D.V. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med 1994, 35:303-316.
35. 111In using monte carlo N-particle computer code: comparison with analytic methods and correlation with in vitro cytotoxicity. J Nucl Med 2010, 51:462-470.
36. Bonner W.M., Redon C.E., Dickey J.S., Nakamura A.J., Sedelnikova O.A., Solier S., et al. GammaH2AX and cancer. Nat Rev Cancer 2008, 8:957-967.